Samsung Biologics Co Ltd (207940) — Free Cash Flow Generation Index
Samsung Biologics Co Ltd (207940) has a Free Cash Flow Generation Index of 0.84x as of June 2026. Free cash flow of ₩525.72 Billion represents 1% of operating cash flow (₩624.80 Billion). Explore how much does Samsung Biologics Co Ltd reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Free Cash Flow Generation Index (2017–2025)
Historical FCF Generation Index trend for Samsung Biologics Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see how efficiently does Samsung Biologics Co Ltd generate cash.
Annual Free Cash Flow Generation for Samsung Biologics Co Ltd (2017–2025)
Year-by-year Free Cash Flow Generation Index for Samsung Biologics Co Ltd. Check 207940 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.34x | ₩772.73 Billion | ₩2.25 Trillion | ₩1.48 Trillion | ▲ +102.5% |
| 2024 | 0.17x | ₩281.73 Billion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -49.6% |
| 2023 | 0.34x | ₩560.90 Billion | ₩1.67 Trillion | ₩1.11 Trillion | ▲ +671.1% |
| 2022 | -0.06x | ₩-56.18 Billion | ₩953.05 Billion | ₩956.84 Billion | ▼ -180.1% |
| 2021 | 0.07x | ₩33.44 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -72.2% |
| 2020 | 0.26x | ₩53.52 Billion | ₩202.09 Billion | ₩139.66 Billion | ▲ +101.6% |
| 2019 | -16.85x | ₩-171.04 Billion | ₩10.15 Billion | ₩192.84 Billion | ▼ -610.9% |
| 2017 | -2.37x | ₩-354.99 Billion | ₩149.82 Billion | ₩494.12 Billion | — |